Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664204 | PMC |
| http://dx.doi.org/10.20411/pai.v8i1.624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reader Comment on: "Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir".
Toxicol Sci
December 2024
Ronald Swanstrom, Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
The Discovery and Preclinical Profile of ALG-000184, a Prodrug of the Potent Hepatitis B Virus Capsid Assembly Modulator ALG-001075.
J Med Chem
December 2024
Aligos Belgium BV, Gaston Geenslaan 1, 3001 Leuven, Belgium.
Chronic hepatitis B (CHB) represents a significant unmet medical need with few options beyond lifelong treatment with nucleoside analogues, which rarely leads to a functional cure. Novel agents that reduce levels of HBV DNA, RNA and other viral antigens could lead to better treatment outcomes. The capsid assembly modulator (CAM) class of compounds represents an important modality for chronic suppression and to improve functional cure rates, either alone or in combination.
View Article and Find Full Text PDFCannabinoid-Inspired Inhibitors of the SARS-CoV-2 Coronavirus 2'--Methyltransferase (2'--MTase) Non-Structural Protein (Nsp10-16).
Molecules
October 2024
Department of Drug Discovery & Biomedical Sciences, Medical University of South Carolina, 280 Calhoun St, Charleston, SC 29425, USA.
Article Synopsis
- Researchers used computer predictions to design antiviral compounds targeting specific proteins (Nsps) in the SARS-CoV-2 virus responsible for mRNA maturation and immune evasion.
- The compound Chromenephenylmethanone-1 (CPM-1), selected for its high specificity, was synthesized and tested, showing impressive results with 98.9% inhibition of the virus and no harmful effects on cells.
- This study highlights the effectiveness of computational modeling in discovering and developing new antiviral drugs against COVID-19.
The structural and mechanistic bases for the viral resistance to allosteric HIV-1 integrase inhibitor pirmitegravir.
mBio
November 2024
Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.
Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are investigational antiretroviral agents that potently impair virion maturation by inducing hyper-multimerization of IN and inhibiting its interaction with viral genomic RNA. The pyrrolopyridine-based ALLINI pirmitegravir (PIR) has recently advanced into phase 2a clinical trials. Previous cell culture-based viral breakthrough assays identified the HIV-1 variant that confers substantial resistance to this inhibitor.
View Article and Find Full Text PDFBiochemical simulation of mutation synthesis and repair during SARS-CoV-2 RNA polymerization.
Virology
December 2024
Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA, 30322, USA; Center for ViroScience and Cure, Children's Healthcare of Atlanta, GA, 30322, USA. Electronic address:
We biochemically simulated the mutation synthesis process of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) complex (nsp7/nsp8/nsp12) involving two sequential mechanistic steps that occur during genomic replication: misinsertion (incorporation of incorrect nucleotides) and mismatch extension. Then, we also simulated mismatch repair process catalyzed by the viral nsp10/nsp14 ExoN complex. In these mechanistic simulations, while SARS-CoV-2 RdRp displays efficient mutation synthesis capability, the viral ExoN complex was able to effectively repair the mismatch primers generated during the mutation synthesis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!